News from boehringer ingelheim vetmedica, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jul 19, 2016, 08:00 ET U.S. FDA expands indication for type 2 diabetes treatment Synjardy® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults

The U.S. Food and Drug Administration has approved an expanded indication for Synjardy® (empagliflozin and metformin hydrochloride) tablets to...


Jul 13, 2016, 08:00 ET Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer

 Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced a new collaboration on a Phase 1b study that will evaluate the...


Jul 01, 2016, 06:00 ET Hall of Fame Member, Joyce L. Morrison, to be Honored With a Times Square, New York City Appearance on July 1, 2016 by Strathmore's Who's Who.

 Joyce L. Morrison of St. Joseph, Missouri, has attained recognition in Strathmore's Who's Who and America's Registry of Outstanding...


Jun 28, 2016, 18:22 ET FDA Advisory Committee recommends approval of Jardiance® (empagliflozin) for cardiovascular indication in 12-11 vote

A U.S. Food and Drug Administration (FDA) Advisory Committee today voted 12-11 that substantial evidence exists to establish that Jardiance®...


Jun 14, 2016, 11:00 ET Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease

 New data showed Jardiance® (empagliflozin) reduced the risk for new-onset or worsening kidney disease by 39 percent versus placebo when...


Jun 12, 2016, 13:00 ET New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes

New analyses showed risk reductions were consistent across age groups for cardiovascular (CV) outcomes, including CV death, with Jardiance®...


Jun 11, 2016, 11:00 ET New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

 Results from the MARLINA-T2D™ trial demonstrated that Tradjenta® (linagliptin), which is marketed by Boehringer Ingelheim and Eli...


Jun 02, 2016, 08:00 ET Boehringer Ingelheim launches ambitious ELUXA trial program to broadly investigate promising lung cancer compound olmutinib

 Boehringer Ingelheim has initiated the ELUXA trial program, designed to further investigate the therapeutic potential of olmutinib (BI...


May 31, 2016, 10:01 ET U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

RIDGEFIELD, Conn. and INDIANAPOLIS, May 31, 2016 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jentadueto® XR...


May 24, 2016, 11:00 ET IL-23 Inhibitor Risankizumab Induces Remission in Phase II Study in Patients with Moderate-to-Severe Crohn's Disease

 Results were presented today from a proof-of-concept, Phase II, randomized, placebo-controlled study (NCT02031276) in Crohn's disease with...


Apr 19, 2016, 05:00 ET Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced plans to conduct two outcome trials investigating the diabetes medicine...


Apr 15, 2016, 16:17 ET FDA approves Gilotrif® (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for...


Apr 08, 2016, 07:00 ET Lancet Publication: New Analysis Demonstrates Only Small Minority of Severe/Very Severe COPD Patients May Benefit from Adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) + LABA Therapy

 Boehringer Ingelheim today announced a new publication showing that levels of white blood cells called eosinophils can help identify patients...


Mar 07, 2016, 08:00 ET AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds

 AbbVie (NYSE: ABBV) and Boehringer Ingelheim today announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23...


Feb 29, 2016, 15:25 ET Boehringer Ingelheim lança medicamento inédito para doença rara e revoluciona panorama de tratamento da Fibrose Pulmonar Idiopática

 A Boehringer Ingelheim, uma das 20 principais farmacêuticas do mundo, anuncia o lançamento de OFEV® (nintedanibe) no Brasil,...


Jan 25, 2016, 08:30 ET U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application for Jardiance® (empagliflozin) based on...


Jan 12, 2016, 16:05 ET Boehringer Ingelheim and Arena Pharmaceuticals Collaborate to Advance Research in Schizophrenia

Boehringer Ingelheim and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that they have signed an exclusive agreement to conduct joint...


Dec 21, 2015, 08:00 ET Boehringer Ingelheim's third generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation for treatment of patients with non-small cell lung cancer

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its...


Dec 21, 2015, 08:00 ET Boehringer Ingelheim's third generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation for treatment of patients with non-small cell lung cancer

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its...


Dec 02, 2015, 08:00 ET Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer

 Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative...


Dec 02, 2015, 08:00 ET Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer

 Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative...


Nov 05, 2015, 13:00 ET Pulmonary Fibrosis Foundation Announces Five Year Partnership With Boehringer Ingelheim To Support Programs Designed To Improve Patient Outcomes

The Pulmonary Fibrosis Foundation (PFF), the leading pulmonary fibrosis resource for patients and their families as well as for the medical...


Sep 28, 2015, 09:33 ET Lilly and Sanofi Reach Settlement Agreement in U.S. Insulin Glargine Litigation

Eli Lilly and Company (NYSE: LLY) has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine...


Aug 27, 2015, 10:30 ET U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

The U.S. Food and Drug Administration (FDA) has approved Synjardy® (empagliflozin and metformin hydrochloride) tablets, from Boehringer...